{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:01Z","timestamp":1787064601240,"version":"build-2736575974"},"reference-count":33,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi Italia","award":["Roscapli"],"award-info":[{"award-number":["Roscapli"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by the formation of anti-ADAMTS13 antibodies. Caplacizumab is approved for the treatment of acute episodes of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. Real-world data for the use of caplacizumab in Italy have been recently published by a limited number of centers located in the northern and middle regions of the country only. Methods: A total of 38 patients with iTTP were enrolled in the study in six Italian centers spread over the entire territory of the country. The patients\u2019 data were registered in eCRF. Results: All patients achieved normalization of platelet count (median 2.0 days, IQR: 2\u20134), within a time significantly shorter than in the absence of caplacizumab, as previously reported in other studies. As to the secondary aims, patients treated with caplacizumab had a few exacerbations (4\/38 (10.5%)) and relapses (2\/38, 5.3%). No deaths or refractoriness were observed in these patients. The total length of hospitalization was 12 days (IQR: 9\u201318) and only one patient required 2 days of stay in the intensive care unit. Interestingly, when caplacizumab was initiated within the first 3 days, the plasma exchange (PEX) duration was 9 days (IQR: 8\u201310), which was significantly lower than those reported in previous studies conducted in the absence of caplacizumab. No severe adverse event was described in the caplacizumab-treated patients. Conclusions: Caplacizumab reduced exacerbations and refractoriness compared with previously reported standard-of-care regimens. When administered in association with PEX and immunosuppressive therapy, caplacizumab provided rapid normalization of platelet count, which was responsible for lower overall hospitalization time, ICU stay, lower exacerbations and relapses compared to previously reported outcomes of studies carried out without caplacizumab.<\/jats:p>","DOI":"10.3390\/jcm13216561","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T11:53:43Z","timestamp":1730462023000},"page":"6561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Luana","family":"Fianchi","sequence":"first","affiliation":[{"name":"Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bonanni","sequence":"additional","affiliation":[{"name":"Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-145X","authenticated-orcid":false,"given":"Alessandra","family":"Borchiellini","sequence":"additional","affiliation":[{"name":"Regional Reference Center for Thrombotic and Haemorrhagic Disorders of Hematology, Division Department of Hematology and Oncology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Valeri","sequence":"additional","affiliation":[{"name":"Regional Reference Center for Thrombotic and Haemorrhagic Disorders of Hematology, Division Department of Hematology and Oncology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-3338","authenticated-orcid":false,"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[{"name":"UOS e Centro di Riferimento Regionale di Malattie Ematologiche Rare, Division of Haematology, A.O.U Policlinico-S. Marco, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Grasso","sequence":"additional","affiliation":[{"name":"UOS e Centro di Riferimento Regionale di Malattie Ematologiche Rare, Division of Haematology, A.O.U Policlinico-S. Marco, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Fozza","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ponta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni L.","family":"Tiscia","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, S. Giovanni Rotondo, and Unit\u00e0 di Ostetricia e Ginecologia, Universit\u00e0 degli Studi di Foggia, 71121 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Grandone","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, S. Giovanni Rotondo, and Unit\u00e0 di Ostetricia e Ginecologia, Universit\u00e0 degli Studi di Foggia, 71121 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, Universitaria di Bologna, 40121 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dedola","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, Universitaria di Bologna, 40121 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Service of Haemorrhagic and Thrombotic Diseases, Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-2691","authenticated-orcid":false,"given":"Monica","family":"Sacco","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica S. Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-9040","authenticated-orcid":false,"given":"Stefano","family":"Lancellotti","sequence":"additional","affiliation":[{"name":"Service of Haemorrhagic and Thrombotic Diseases, Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-8849","authenticated-orcid":false,"given":"Raimondo","family":"De Cristofaro","sequence":"additional","affiliation":[{"name":"Service of Haemorrhagic and Thrombotic Diseases, Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS, 00168 Rome, Italy"},{"name":"Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica S. Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Clinical practice. Thrombotic thrombocytopenic purpura","volume":"354","author":"George","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"Kuhne","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"Knoebl","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.rpth.2023.102185","article-title":"Caplacizumab use for immune thrombotic thrombocytopenic purpura: The Milan thrombotic thrombocytopenic purpura registry","volume":"7","author":"Agosti","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Angelucci, E., Artoni, A., Fianchi, L., Dovizio, M., Iacolare, B., Saragoni, S., and Esposti, L.D. (2024). Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy. J. Clin. Med., 13.","DOI":"10.20944\/preprints202401.1937.v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/bloodadvances.2024013488","article-title":"Caplacizumab in paediatric immune thrombotic thrombocytopenic purpura (iTTP): The UK TTP Registry experience","volume":"8","author":"Taylor","year":"2024","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"Volker","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura","volume":"381","author":"Chander","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange","volume":"144","author":"Kuhne","year":"2024","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: An international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Van de Louw, A., Mariotte, E., Darmon, M., Cohrs, A., Leslie, D., and Azoulay, E. (2021). Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0256024"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MBC.0000000000001313","article-title":"Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: A systematic review and meta-analysis","volume":"35","author":"Peng","year":"2024","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1526-0968.2002.00363.x","article-title":"Myocardial infarction\/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: The Indiana University experience","volume":"6","author":"McCarthy","year":"2002","journal-title":"Ther. Apher."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.18127","article-title":"Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura","volume":"197","author":"Shaw","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: Correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_24","first-page":"325","article-title":"Silent cerebral infarction during immune TTP remission: Prevalence, predictors, and impact on cognition","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/clc.20731","article-title":"Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: A single-center experience","volume":"33","author":"Gandhi","year":"2010","journal-title":"Clin. Cardiol."},{"key":"ref_26","first-page":"43","article-title":"Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy","volume":"8","author":"Ravasio","year":"2021","journal-title":"Glob. Reg. Health Technol. Assess."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/jth.15009","article-title":"Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2023010807","article-title":"A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.thromres.2020.05.045","article-title":"Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: A 10-year provincial retrospective cohort study","volume":"193","author":"Sawler","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"Volker","year":"2023","journal-title":"J. Thromb. Haemost."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:25:30Z","timestamp":1760113530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":33,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216561"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216561","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}